In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of “Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia.” 

Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood and accounts for approximately 30% of all cancers diagnosed before the age of 18 years. The primary cause of death for ALL patients is disease relapse. Therefore, monitoring for minimal residual disease (MRD) is considered the most powerful predictor of outcome in acute leukemias.

Rolf Muller, CEO of BioFluidica, states that with BioFluidica’s technology, “We are able to program microfluidic chips to isolate any kind of diagnostically relevant cell from blood samples, whether from solid tumors or blood cancer.  In the case of ALL we are detecting complex panels of Circulating Leukemic Cells (CLCs) to monitor cancer recurrence. The expansion of BioFluidica’s technology into the blood-born cancers is added to the clinical validation we have already achieved from 9 other cancers including lung, breast, pancreatic, prostate, and colorectal cancer. The high through-put instrumentation for cell isolation will now be used in clinical trials.”



Core Screening Facility #1
10835 Road to the Cure
Suite 150
San Diego, Ca. 92121

“The Liquid Scan ®, hope for millions.”


Cision View original content to download multimedia:

SOURCE BioFluidica

Click to view original post